{Reference Type}: Journal Article
{Title}: Multicenter Observational Study on Metastatic Non-Small Cell Lung Cancer Harboring BRAF Mutations: Focus on Clinical Characteristics and Treatment Outcome of V600E and Non-V600E Subgroups.
{Author}: Perrone F;Mazzaschi G;Minari R;Verzè M;Azzoni C;Bottarelli L;Nizzoli R;Pluchino M;Altimari A;Gruppioni E;Sperandi F;Andrini E;Guaitoli G;Bertolini F;Barbieri F;Bettelli S;Longo L;Pagano M;Bonelli C;Tagliavini E;Nicoli D;Ubiali A;Zangrandi A;Trubini S;Proietto M;Gnetti L;Tiseo M;
{Journal}: Cancers (Basel)
{Volume}: 14
{Issue}: 8
{Year}: Apr 2022 16
{Factor}: 6.575
{DOI}: 10.3390/cancers14082019
{Abstract}: <B>BACKGROUND: </B>BRAF mutation involved 2-4% of lung adenocarcinoma. Differences in clinicopathologic features and patient outcome exist between V600E and non-V600E BRAF mutated NSCLC. Thus, we sought to assess the frequency and clinical relevance of BRAF mutations in a real-life population of advanced-NSCLC, investigating the potential prognostic significance of distinct genetic alterations.<BR><B>METHODS: </B>The present multicenter Italian retrospective study involved advanced BRAF mutant NSCLC. Complete clinicopathologic data were evaluated for BRAF V600E and non-V600E patients.<BR><B>RESULTS: </B>A total of 44 BRAFmut NSCLC patients were included (V600E, n = 23; non-V600E, n = 21). No significant differences in survival outcome and treatment response were documented, according to V600E vs. non-V600E mutations, although a trend towards prolonged PFS was observed in the V600E subgroup (median PFS = 11.3 vs. 6.0 months in non-V600E). In the overall population, ECOG PS and age significantly impacted on OS, while bone lesions were associated with shorter PFS. Compared to immunotherapy, first-line chemotherapy was associated with longer OS in the overall population, and especially in the BRAF V600E subtype.<BR><B>CONCLUSIONS: </B>Here, we report on real-life data from a retrospective cohort of advanced-NSCLC harboring BRAF alterations. Our study offers relevant clues on survival outcome, therapeutic response, and clinicopathologic correlations of BRAF-mutant NSCLC.